VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US
China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...
Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...
NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms
The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...
Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy
China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...
Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors
China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...
Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M
Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...
MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC
The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...
Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial
Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...
ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor
Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...
Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment
China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...
Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product
Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...
GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...
Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China
China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...